K
KASHIV BIOSCIENCES PRIVATE LTD.
Since its establishment in 2011, Kashiv BioSciences has evolved into a premier, fully integrated biopharmaceutical company offering next-generation drug delivery technologies, biosimilars, and specialty biopharmaceutical products. Kashiv is built on patient-focused innovation and leverages its expertise in small and large molecules to develop a clinically differentiated pipeline of novel compounds and biosimilars with lead candidates in various therapeutic areas, including CNS, endocrinology, cancer, and several debilitating orphan diseases. Kashiv plans to commercialize its products via strategic partnerships, and for select products, through the creation of an in-house specialized sales and marketing organization.
Country/Area ：India
Company Email ：office@kashivbiosciences.com
Industry ：ServicesBusiness Services
Company address ：20 New England Ave, Piscataway, New Jersey, 08854, United States
Company website ：*****
Established ：2006
Company Revenue ：$27,264,000
Number of employees ：142
SIC Code ：28283
NAICS Code ：32325
Company News
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Oct 3, 2023
PISCATAWAY, N.J. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company, and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have entered into an exclusive licensing agreement for ADL018 (also called AVT23), a proposed biosimilar to Xolair® (omalizumab), which is in clinical development. The agreement covers a
Oct 3, 2023
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)Oct 2, 2023
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has enrolled the first patient in its Phase III clinical study involving ADL018, the Company’s biosimilar candidate to XOLAIR®. The objective of the study is to compare ADL018 and XOLAIR® in terms of efficacy, safety, tolerability, and immunogenicity in patients with chronic idiopathic/spontaneous urticaria (CSU) who remain symptomatic on H1 antihistamine treatment. The study is expect
Oct 2, 2023Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)Jul 5, 2023
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair ® (omalizumab)
Jul 5, 2023Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)May 31, 2022
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Kashiv Biosciences, LLC (“Kashiv” or the “Company”) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved its Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®. The product will be marketed under the proprietary name FYLNETRA®. FYLNETRA was developed by Kashiv in Chicago, Illinois in collaboration with Amneal Pharmaceuticals, Inc. (“Amneal”). It is used to treat neutropenia (low n
May 31, 2022Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)Mar 2, 2022
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®. The product will be marketed under the proprietary name RELEUKOTM. RELEUKOTM was developed in collaboration with Amneal Pharmaceuticals, Inc. and is expected to launch in the third quarter of 2022. It is used to treat neutropenia (low neutrophils which are a t
Mar 2, 2022Web Summary
Q1: What is the address of Kashiv BioSciences' headquarters?
A1: The address of Kashiv BioSciences' headquarters is 20 New England Ave, Piscataway, NJ 08854.
Q2: What type of company is Kashiv BioSciences?
A2: Kashiv BioSciences is a fully-integrated biopharmaceutical company that operates globally with robust infrastructure and highly skilled teams providing R&D, clinical, manufacturing, regulatory, and IP capabilities.
Q3: What products does Kashiv BioSciences develop and manufacture?
A3: Kashiv BioSciences develops and manufactures biosimilars, which are affordable versions of biologics used to treat various diseases. The company has a pipeline of internally developed products and is also evaluating in-licensing opportunities for biosimilars that have completed analytical similarity testing with innovator-branded biologics.
Q4: What services does Kashiv BioSciences offer?
A4: Kashiv BioSciences offers commercialization services, including licensing, strategic partnering, or profit-sharing joint ventures, to its partners. The company also provides regulatory and intellectual property (IP) capabilities to support the development and launch of its biosimilars.
Q5: What is the contact information for Kashiv BioSciences?
A5: The contact information for Kashiv BioSciences includes phone number +1 732-475-0500, email address info@kashivbio.com, and physical addresses in Piscataway, New Jersey; Chicago, Illinois; and Ahmedabad, Gujarat, India.
Q6: What is the mission of Kashiv BioSciences?
A6: The mission of Kashiv BioSciences is to become the trusted choice of high-quality, affordable biosimilars for patients worldwide. The company aims to lead with science to accelerate development and drive manufacturing efficiency in the field of biosimilars.
Q7: What is the vision of Kashiv BioSciences?
A7: The vision of Kashiv BioSciences is to forge a healthier world through accessible biologics, leveraging its people, partners, and shared purpose to advance patient care and access to important medicines.
Q8: How many employees does Kashiv BioSciences have?
A8: According to the company's information, Kashiv BioSciences has over 350 employees across its global operations.
A1: The address of Kashiv BioSciences' headquarters is 20 New England Ave, Piscataway, NJ 08854.
Q2: What type of company is Kashiv BioSciences?
A2: Kashiv BioSciences is a fully-integrated biopharmaceutical company that operates globally with robust infrastructure and highly skilled teams providing R&D, clinical, manufacturing, regulatory, and IP capabilities.
Q3: What products does Kashiv BioSciences develop and manufacture?
A3: Kashiv BioSciences develops and manufactures biosimilars, which are affordable versions of biologics used to treat various diseases. The company has a pipeline of internally developed products and is also evaluating in-licensing opportunities for biosimilars that have completed analytical similarity testing with innovator-branded biologics.
Q4: What services does Kashiv BioSciences offer?
A4: Kashiv BioSciences offers commercialization services, including licensing, strategic partnering, or profit-sharing joint ventures, to its partners. The company also provides regulatory and intellectual property (IP) capabilities to support the development and launch of its biosimilars.
Q5: What is the contact information for Kashiv BioSciences?
A5: The contact information for Kashiv BioSciences includes phone number +1 732-475-0500, email address info@kashivbio.com, and physical addresses in Piscataway, New Jersey; Chicago, Illinois; and Ahmedabad, Gujarat, India.
Q6: What is the mission of Kashiv BioSciences?
A6: The mission of Kashiv BioSciences is to become the trusted choice of high-quality, affordable biosimilars for patients worldwide. The company aims to lead with science to accelerate development and drive manufacturing efficiency in the field of biosimilars.
Q7: What is the vision of Kashiv BioSciences?
A7: The vision of Kashiv BioSciences is to forge a healthier world through accessible biologics, leveraging its people, partners, and shared purpose to advance patient care and access to important medicines.
Q8: How many employees does Kashiv BioSciences have?
A8: According to the company's information, Kashiv BioSciences has over 350 employees across its global operations.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
